Your browser version may not work well with NCBI's Web applications. More information here...
1: Dig Dis Sci. 2000 Aug;45(8):1578-84.Click here to read Links

5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer.

Brown WA, Farmer KC, Skinner SA, Malcontenti-Wilson C, Misajon A, O'Brien PE.

Monash University Department of Surgery, Alfred Hospital, Prahran, Victoria, Australia.

The ability of 5-aminosalicylic acid and olsalazine to inhibit colonic aberrant crypts and tumors was investigated in 1,2-dimethylhydrazine-treated rats. The effect of these drugs on the rates of tumor apoptosis and proliferation was studied as potential mechanisms for their action. 5-Aminosalicylic acid reduced the number of aberrant crypt foci by over one third, while olsalazine had no effect on this parameter. However, both agents effectively reduced tumor number and load, increased the rate of tumor apoptosis, and reduced the rate of tumor cell proliferation. In conclusion, 5-aminosalicylic acid and olsalazine are both ultimately effective chemopreventive agents in this model; however, only 5-aminosalicylic acid inhibited the formation of aberrant crypt foci. The inhibitory effect of these agents in tumors is related to the inhibition of proliferation and the induction of apoptosis.

PMID: 11007109 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Mesalamine (Asacol® , Canasa® , Pentasa® , ...)

    Mesalamine is used to treat ulcerative colitis (a condition in which part or all of the lining of the colon [large intestine] is swollen or worn away). Mesalamine delayed-release tablets and controlled-release capsules m...

  • Olsalazine (Dipentum® )

    Olsalazine, an anti-inflammatory medicine, is used to treat ulcerative colitis, a condition in which the bowel is inflamed. Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdo...

  • Source: AHFS Consumer Medication Information